Side-by-side comparison of AI visibility scores, market position, and capabilities
bit.bio is a Cambridge, UK synthetic biology company using its proprietary opti-ox technology to reprogram stem cells into any human cell type at scale and with high consistency;
bit.bio is a synthetic biology company founded in 2016 as a spinout from the Luscher laboratory at the University of Cambridge, headquartered in Cambridge, United Kingdom. The company's core technology platform, opti-ox (optimized overexpression), enables the precise and highly reproducible reprogramming of human induced pluripotent stem cells (iPSCs) into virtually any human cell type — neurons, cardiomyocytes, hepatocytes, immune cells, and more — with a consistency and scalability that has historically been impossible to achieve with conventional differentiation protocols. This precision is achieved by engineering the transcription factor expression cassette into a defined genomic safe harbor site, ensuring every cell in a batch receives the same reprogramming instruction.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.